Role of Leptin in the Neuroendocrine and Immune Response to Fasting
Role of Leptin in the Neuroendocrine and Immune Response to Fasting in Humans
Sponsor: Amgen
Listed as NCT00140231, this PHASE1/PHASE2 trial focuses on Fasting and remains completed. Sponsored by Amgen, it has been updated 10 times since 2002, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Feb 2017 — Jul 2017 [monthly]
Unknown Status PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Oct 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Beth Israel Deaconess Medical Center
- National Center for Research Resources (NCRR)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
For direct contact, visit the study record on ClinicalTrials.gov .